GLP-1 Medications and Chronic
Kidney Disease

CKD and obesity frequently coexist, but a favorable trial headline does not replace kidney testing, medication review, or individualized prescribing. The safest way to interpret this evidence is to ask three questions: which exact product is being discussed, which population was studied, and what monitoring plan addresses both expected benefits and dehydration-related kidney risk.

CKD basics: eGFR, urine albumin, and chronicity

CKD is an abnormality of kidney structure or function present for at least three months. Clinicians classify it by cause, glomerular filtration rate category, and albuminuria category. A single abnormal result can reflect an acute illness or temporary kidney injury; trends and repeat testing help establish chronicity.^{[3] [4]}

Estimated glomerular filtration rate (eGFR) estimates filtering capacity from a blood creatinine measurement and other inputs. NIDDK explains that eGFR below 60 mL/min/1.73 m² may indicate kidney disease, while 15 or below is kidney-failure territory, when many people need dialysis or transplantation. It is an estimate, not a direct measurement.^[3]

Urine albumin-to-creatinine ratio (UACR) looks for albumin leaking into urine while accounting for urine concentration. NIDDK describes 30 mg/g or less as normal; a result over 30 mg/g may indicate kidney disease and is commonly confirmed. eGFR and UACR answer different questions: filtering capacity and kidney damage. Both the level and direction over time matter.^[3]

What the FLOW kidney-outcome trial found

FLOW was a randomized, double-blind trial of 3,533 adults with type 2 diabetes and albuminuric CKD. Participants received semaglutide 1.0 mg once weekly or placebo, with median follow-up of 3.4 years. Most were receiving a maximally labeled or tolerated ACE inhibitor or ARB unless contraindicated or not tolerated. This was a dedicated kidney-outcome trial, not a general study of all people with obesity or every cause of CKD.^{[1] [5] [6]}

The primary composite included kidney failure, a sustained eGFR decline of at least 50%, or kidney-related or cardiovascular death. It occurred in 331 of 1,767 semaglutide participants (18.7%) and 410 of 1,766 placebo participants (23.2%). The hazard ratio was 0.76, described as a 24% relative reduction in hazard; the observed difference in first events was 4.5 percentage points.^{[1] [5]}

Annual eGFR decline was slower by 1.16 mL/min/1.73 m² in the semaglutide group. Supportive cardiovascular- and mortality-related outcomes also favored semaglutide. Precision still matters: the primary endpoint combined kidney and death outcomes, and some individual kidney components had few events or confidence intervals crossing 1.0. FLOW supports the composite result in the enrolled population; it does not prove prevention of every component in every patient.^{[1] [5]}

Who the strongest evidence applies to

FLOW enrolled adults with type 2 diabetes and substantial albuminuria: eGFR 50–75 with UACR above 300 mg/g, or eGFR 25 to under 50 with UACR above 100 mg/g. It did not directly enroll people with eGFR below 25 at entry or people already receiving chronic dialysis. Only 11% had baseline eGFR below 30. The trial therefore cannot answer every question about non-albuminuric CKD, very advanced CKD, dialysis, kidney transplantation, or CKD without type 2 diabetes.^{[1] [6]}

The product distinction is equally important. The current Ozempic label includes the type 2 diabetes-and-CKD indication. The current Wegovy label covers long-term weight reduction in eligible patients and reduction of major cardiovascular events in adults with established cardiovascular disease plus obesity or overweight; CKD treatment is not listed as a Wegovy indication.^{[1] [2]}

SELECT adds encouraging but different evidence. It enrolled 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity but no diabetes. A prespecified kidney analysis found a five-component kidney endpoint in 1.8% with semaglutide 2.4 mg and 2.2% with placebo. This was a secondary analysis of a cardiovascular trial with relatively few kidney events, not a dedicated CKD-progression trial, and end-stage kidney disease or dialysis was excluded.^[7]

Why kidney benefit does not remove kidney safety concerns

Ozempic and Wegovy labeling warns of postmarketing acute kidney injury, sometimes requiring hemodialysis. Most reported events occurred in people with nausea, vomiting, or diarrhea that led to dehydration. The labels direct clinicians to monitor renal function when adverse reactions could cause volume depletion, especially during initiation and dose escalation.^{[1] [2]}

For someone with CKD, persistent gastrointestinal symptoms should not be treated as a routine inconvenience. Patients should follow their clinician’s hydration and sick-day plan and report persistent or extended nausea, vomiting, or diarrhea, inability to keep fluids down, reduced urination, fainting, or other possible acute kidney injury symptoms promptly. Severe abdominal pain—with or without nausea or vomiting—also warrants prompt medical contact because it can signal pancreatitis.^{[1] [2]}

A sick-day plan should be written before illness, not improvised during it. KDIGO says that when medicines are temporarily stopped during an acute illness, there should be a clear plan for restarting them. It does not give a universal instruction to stop every GLP-1 medicine whenever someone is unwell. The prescriber should decide what to hold, what to continue, and when laboratory testing or urgent evaluation is needed.^[4]

Medication review and monitoring questions

CKD regimens can be complex. KDIGO recommends thorough medication review at intervals and care transitions to assess ongoing indication, adherence, interactions, and safety. The prescriber should know the person’s eGFR and UACR trend, diabetes medicines, blood-pressure medicines, over-the-counter drugs, supplements, recent illnesses, and who manages kidney care.^[4]

1. Which exact product and indication are being considered? Confirm whether the goal is diabetes care, weight management, cardiovascular risk reduction, or another indication.
2. What is my current kidney stage and albuminuria category? Ask how recent results compare with earlier tests.
3. How will gastrointestinal symptoms be handled? Define the hydration plan, contact threshold, and laboratory follow-up during dose escalation.
4. Could other diabetes medicines require adjustment? Semaglutide with insulin or a sulfonylurea can increase hypoglycemia risk; dose reduction of those agents may be needed.
5. Who coordinates care? Clarify when the prescriber, primary-care clinician, nephrologist, or urgent-care team should be contacted.

Semaglutide delays gastric emptying and may affect absorption of oral medicines, so its label advises caution. Monitoring frequency is individualized, but CKD follow-up generally considers both eGFR and UACR rather than treating one result as a complete verdict.^{[1] [3] [4]}

Evidence limits and compounded-product boundaries

FLOW used protocol-supplied semaglutide 1.0 mg and SELECT used semaglutide 2.4 mg. Those results do not establish the exposure, quality, safety, or kidney outcomes of an unapproved compounded product. FDA says compounded drugs are not FDA approved and do not undergo premarket review for safety, effectiveness, or quality.^[8]

FDA has reported dosing errors with compounded injectable semaglutide, some requiring hospitalization, and notes that concentrations, containers, instructions, and ingredients may differ. The agency also says some compounders use semaglutide sodium or acetate, which are different active ingredients from the base form used in approved drugs; FDA does not have information establishing the same chemical and pharmacologic properties.^{[8] [9]}

The sound conclusion is narrower than “GLP-1s protect kidneys.” In adults with type 2 diabetes and albuminuric CKD resembling FLOW participants, Ozempic has FDA-reviewed kidney-outcome evidence and an approved kidney-related indication. For other populations and products, clinicians should interpret the exact evidence, indication, kidney stage, comorbidities, and treatment risks rather than extrapolating a class headline.

Frequently asked questions